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Rationale: 1994, selected patients(pts) early stage IIIA-NSCLC 
(operable, 1-2 LN involved at mediastinoscopy, no clinical N2, no 
bulky/extranodal disease) were taken to upfront surgery(S) at centers 
in Europe/North America. We compared this approach to aggressive 
tri-modality therapy - induction chemotherapy(CTx), preoperative 
radiochemotherapy(RTx/CTx) and deﬁnitive S - in a multicenter ran-
domized GERMAN KREBSHILFE trial (full trials grant).
Patients and Methods: operable IIIA pts (criteria above, mediasti-
noscopy, central T3N0-1, WHO 0,1) stratiﬁed (TN-group, center) and 
randomized: arm A - S and postoperative RTx (50-60 Gy); arm B - in-
duction CTx (3 x cisplatin(P) 60 mg/m2 d 1+7/etoposide(E) 150 mg/m2 
d 3,4,5) + concurrent RTx/CTx (45 Gy; 1.5 Gy bid; 1 x P 50 mg/m2 d 2 
+ 9, E 100 mg/m2 d 4,5,6) + S (+ prophylactic cranial irradiation (PCI) 
- 15 x 2 Gy = 30 Gy in 3 wks) (preliminary data: Eberhardt et al, Lung 
Cancer 2003;41:S63(O-213), Suppl 2).
Results: 11/94 to 7/01 112 pts randomized. 6 pts (3/arm) not eligible 
(misstaging, pts refusal, early progression prior any study therapy). 106 
pts eligible for complete analysis 3/2007: Pts characteristics M 90 F 16; 
age median (med) 59 (37-71); SCC 55 adeno-ca 35 LCC 16; A: n = 51 
pts T3N0-1 3 T1-2N2 38 T3N2 10; B: n = 55 pts T3N0-1 3 T1-2N2 45 
T3N2 7. A: S 50/50 probatory thoracotomy (PT) 5/50 R1/2 10/50 com-
plete resection (R0) 35/50; B: S 39/54 PT 1/54 R1/2 6/54 R0 32/54; 
peri- and postoperative morbidity/mortality not signiﬁcantly different 
between A/B (rate of early postoperative deaths, infections, stump 
insufﬁciencies, bleeding, embolisms, postop duration of hospitalization, 
time on postop respirator, time on ICU). Strong trend for more limited 
surgical resections following induction: number of pneumonectomies: 
A 22,B 11. Although terminated early due to slow accrual/emerging 
data for adjuvant CTx(IALT), the survival(surv) results as follows: 
median(med) overall surv: A 15 mo vs B 29 mo (p = 0.15 Wilcoxon 
W); med event-free surv: 9 mo vs 15 mo (p = 0.12 W); med disease 
speciﬁc(spec) surv 10 mo vs 18 mo ( p = 0.026 W). 5-year overall surv 
18% vs 16%; event-free surv: 20% vs 24%; disease spec surv 23% vs 
24%. Beyond 3 yrs from randomization intercurrent events (co-mor-
bidities) and second cancers predominant reason for deaths. Med surv 
of pts still alive 3/07: 94 mo(n = 14,73+-149+). 
Conclusion: This tri-modality protocol was feasible/safe in the mul-
ticenter setting. S following complex bi-modality induction did not 
show increased morbidity/mortality. Strong trend towards lung-sparing 
surgery in the arm with preoperative complex induction (down-staging? 
organ-sparing effect?). Results of this trial mandate rate of less exten-
sive S interventions (eg. lobectomies) as further important endpoint to 
be added within clinical trials of comparable pts populations (signiﬁ-
cant risk for pneumonectomy at thoracotomy). Although surv data 
favoured tri-modality in the ﬁrst four yrs - overall no of pts randomized 
does not allow valid conclusions concerning this endpoint. Currently, 
data on brain-relapse -free surv are analyzed with different policy for 
PCI in both arms (PCI vs no PCI). 
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Background: Surgical resection in patients with stage IIIA-pN2 
NSCLC is usually reserved for patients with downstaging of medi-
astinal lymph nodes (LNs) after induction therapy. However, clinical 
restaging after induction therapy is often inaccurate. Moreover, there 
are insufﬁcient data to exclude all patients with persistent mediastinal 
disease from surgery. Assuming baseline endoscopic mediastinal stag-
ing in the near future, we explored a restaging strategy combining tis-
sue analysis of mediastinal LNs obtained post-induction, and FDG-PET 
for monitoring response in the primary tumour.
Methods: Baseline and repeat PET after three cycles of induc-
tion chemotherapy, as well as complete resection specimens of both 
mediastinal LNs and primary tumour, were available in 30 patients 
out of our prospective database of surgical multimodality therapy in 
IIIA-pN2 NSCLC patients (period: 04-1995 to 06-2002; ref. Lorent et 
al, Ann Oncol 15:1645, 2004). In these 30 patients, histological tumour 
grading of both LNs and primary tumour was performed by means 
of conventional morphometric procedures based on a point counting 
technique, as described by Gundersen (ref. Gundersen et al, APMIS 
96:379, 1988). Three morphometric grading groups were considered: 
mediastinal downstaging (clearance of mediastinal disease), ‘minor’ 
residual mediastinal disease (<10% viable tumour cells) and ‘major’ 
residual mediastinal disease (>10% viable tumour cells). These medias-
tinal morphometric grading groups, together with the percent decrease 
of SUVmax of the primary tumour, were correlated with survival to 
establish an algorithm for prognostic restaging.
Results: The median and 5-year overall survival for the 30 patients was 
36.4 months and 30%, respectively. The median decrease of SUVmax 
on the primary tumour between baseline and repeat PET scan was 
60%, and this value was used as cut-off. A >60% decrease compared 
to a <60% decrease of SUVmax resulted in a median survival time of 
57.5 versus 18.3 months and 5-year overall survival 47% versus 13%, 
respectively; log-rank p=0.01, HR 0.34 (95%CI 0.12-0.74). No patient 
with ‘major’ residual mediastinal disease survived 5 years, while 5-year 
overall survival was 43% both in patients with mediastinal clearance as 
well as in those with ‘minor’ residual mediastinal disease. Combined 
prognostic stratiﬁcation resulted in two subgroups: patients with down-
staging or persistent ‘minor’ mediastinal LN involvement and >60% 
decrease of SUVmax on the primary tumour were allocated as ‘Good 
Prognosis group’ (n=13). Patients with downstaging or persistent 
‘minor’ mediastinal LN involvement and <60% decrease of SUVmax 
on the primary tumour were pooled with patients having persistent 
‘major’ mediastinal LN involvement and allocated as ‘Poor Prognosis 
group’ (n=17). The median and 5-year overall survival for these Good 
and Poor Prognosis groups were “not reached” versus 18.3 months, 
and 62% versus 6%, respectively; log-rank p<0.0001, HR 0.18 (95%CI 
0.06-0.38). 
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Conclusions: These data suggest: (1) persistent ‘minor’ pN2-disease 
following induction chemotherapy does not always exclude favourable 
outcome after surgery; (2) serial FDG-PET is able to select surgical 
candidates amongst patients with persistent ‘minor’ pN2-disease or 
with mediastinal clearance; (3) persistent ‘major’ pN2-disease has a 
poor prognosis and should not be considered for surgery.
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Background: The T2 descriptor in the AJCC staging for non-small-
cell lung cancer (NSCLC) contains several non-size based criteria in 
addition to the criterion of tumor size greater than 3 cm. It remains un-
known if there are survival differences between patients whose tumors 
were staged according to these non-size based criteria when compared 
to patients whose tumors were staged according to tumor size.
Methods: We analyzed 10,545 stage IB NSCLC patients from the Cali-
fornia Cancer Registry (CCR) from 1989 to 2003. These patients were 
staged as IB disease according to three non-overlapping main criteria: 
1) tumor size [T2S]; 2) visceral pleura invasion, hilar atelectasis or 
obstructive pneumonitis [T2P]; 3) main bronchus involvement ≥ 2 cm 
from the carina [T2C]. Univariate survival analyses were conducted 
using the Kaplan-Meier method. Multivariate survival analyses were 
performed using Cox proportional hazards ratios.
Results: 5385 (51.1%) IB patients were staged according to tumor size 
[T2S], 4557 (43.2%) patients were staged by visceral pleura invasion, 
hilar atelectasis or obstructive pneumonitis [T2P] and 603 (5.7%) 
patients were staged by main bronchus involvement ≥ 2 cm from the 
carina [T2C]. 35.7% of the IB patients due to visceral pleura invasion, 
hilar atelectasis or obstructive pneumonitis [T2P] and 29.7% of the pa-
tients due to main bronchus involvement ≥ 2 cm from the carina [T2C] 
had tumors 3 cm or smaller. There was statistical significant difference 
in the 5-year survivorship and median overall survival (OS) among the 
3 types of stage IB NSCLC patients: (T2C: 38.6% and 39 months; T2P: 
38.0% and 38 months; T2C: 40.3% and 39 months; P = 0.0031). The 
5-year survival and median OS of these IB patients with tumor 3 cm or 
smaller were 53.3% and 67 months for T2P and 52.6% and 73 months 
for T2C respectively, similar to the 53.2% 5-year survival and 67 
months of median OS for stage IA patients. Cox proportional hazards 
model revealed that T2P > 3 cm is a poor prognostic factor (vs. T2S, 
Hazard Ratio [HR] = 1.13, 95% Confidence Interval (CI) = 1.06-1.20) 
while T2P ≤ 3 cm was a favorable prognostic factor (vs. T2S, HR = 
0.87, 95% CI = 0.80-0.95). T2C > 3 cm (vs. T2S, HR = 0.98, 95% CI = 
0.84-1.13) and T2C ≤ 3 cm (vs. T2S, HR = 0.86, 95% CI = 0.69-1.08) 
were not independent poor prognostic factors.
Conclusions: Non-size based T2 descriptors-visceral pleura inva-
sion, hilar atelectasis or obstructive pneumonitis are poor independent 
prognostic factors when the tumor size was greater than 3 cm. Stage IB 
NSCLC patients staged by non-size based criteria T2 descriptors whose 
tumors were 3 cm or smaller had survival similar to stage IA NSCLC 
patients. Future proposed changes to the AJCC T2 descriptor, the 
non-size based criteria should be linked to size criteria rather than as 
independent criteria. The prognostic signiﬁcance of the T2C criterion 
requries further studies.
Cox proportional hazards model showing prognostic signiﬁcance of 
various AJCC T2 descrpitors.
T2 descriptor
Number of 
patients
Hazard ratio
95% Conﬁdence 
interval
P-value
T2S 5385 1.00   
T2P > 3 cm 2960 1.127 (1.056-1.202) 0.0003
T2P ≤ 3 cm 1597 0.869 (0.796-0.948) 0.0016
T2C > 3 cm 424 0.975 (0.841-1.130) 0.7343
T2C ≤ 3 cm 179 0.863 (0.693-1.075) 0.1895
 
Adjustment included: age at diagnosis, gender, race, socioeconomic 
status, marital status, histology, histologic grade, tumor lobar location, 
surgical treatment, chemotherapy and radiation.
T2S-T2 descriptor: by size only
T2P-T2 descriptor: visceral pleura invasion, hilar atelectasis or obstruc-
tive pneumonitis
T2C-T2 descriptor: main bronchus involvement ≥ 2 cm from carina
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Preliminary experience with mediastinal staging of patients with 
non-small cell lung cancer using endobronchial ultrasound (EBUS/
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Background: Treatment and prognosis of patients with non-small 
cell lung cancer depend on the stage of the disease at the time of the 
diagnosis. Mediastinoscopy has been the golden standard for staging of 
the mediastinum for many years, and it has been proven that the false 
negative rate of N2-disease by this procedure is near 20% or more. The 
consequence of this is often a futile thoracotomy without beneﬁt for the 
patient. 
We would like to report the results of our preliminary experience with 
EBUS/TBNA for staging of the mediastinum. 
Methods: A total of 152 consecutive patients were examined by 
EBUS/TBNA during the ﬁrst year (2006) the method was used in our 
department. The indication was mediastinal staging in 82 patients 
(53.9%). The remaining 70 patients were examined because of an 
undiagnosed mediastinal mass, follow-up after resection of NSCLC, or 
restaging after chemotherapy. The 3 examiners had no previous experi-
ence with endoscopic ultrasound, but were trained for a period of 2 
days in another institution with experience in the method. 
The examinations of the 82 patients were carried out in general an-
aesthesia with a linear scanner (BF-UC160F, Olympus). Cytological 
samples were taken by 22G needle aspiration (NA-201SX-4022, Olym-
pus) from all lymph node stations visualized. Patients positive for N2 
or N3-disease (n=32) by EBUS/TBNA were not examined further, but 
referred to oncological treatment. Patients without N2 or N3-disease 
